RE:RE:RE:RE:Guggenheim raises Merck US (MSD) to a buy on KeytrudaNoteable wrote: Seamus Fernandez Senior Managing Director of Guggenheim's Healthcare Research team specifically made note that Keytuda PD-1 in an I/O combination “would be a substantial value-enhancing event”, and that was a significant reason for the the firm's BUY recommendation. Unlike you, that's plenty enough substantiation for those in the know!
Blah blah blah... we want to know if pela has any value... at the less than 70m!